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Abstract
The KIT-inhibitor imatinib mesylate (IM) has greatly improved the treatment of metastatic gastrointestinal stromal tumors
(GIST). IM exhibits strong antiproliferative effects but fails to induce sufficient levels of apoptosis resulting in low pathologic
complete remission rates and a high rate of secondary progression in the metastatic setting. Upregulation of p53 by MDM2
inhibitors has been shown to induce apoptosis in p53 wildtype tumors. Analyzing a series of 62 mostly untreated, localized
and metastatic GIST we detected a low rate (3%) of inactivating p53 mutations, thus providing a rationale for further
exploration of p53-directed therapeutic strategies. To this end, we studied nutlin-3, an inhibitor of the p53 antagonist
MDM2, and RITA, a putative p53 activator, in GIST cell lines. Nutlin-3 effectively induced p53 at therapeutically relevant
levels, which resulted in moderate antiproliferative effects and cell cycle arrest in p53 wildtype GIST cell lines GIST430,
GIST48 and GIST48B. P53 reactivation substantially improved the apoptotic response after effective KIT inhibition with
sunitinib and 17-AAG in IM-resistant cell lines. The commonly used imatinib-sensitive cell lines GIST882 and GIST-T1 were
shown to harbor defective p53 and therefore failed to respond to nutlin-3 treatment. RITA induced p53 in GIST48B, followed
by antiproliferative effects and a strong induction of apoptosis. Surprisingly, GIST-T1 was also highly sensitive to RITA
despite lacking functional p53. This suggested a more complex, p53-independent mechanism of action for the latter
compound. No antagonistic effects from p53-activating drugs were seen with any drug combination. Our data provide first
evidence that modulation of the MDM2/p53 pathway may be therapeutically useful to improve the apoptotic response of
KIT-inhibitory drugs in the treatment of naı ¨ve GIST, with p53 mutation status being a predictive factor of response.
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Introduction
Gastrointestinal stromal tumors (GISTs) are the most frequent
mesenchymal neoplasms of the gastrointestinal tract [1] and are
characterized by activating mutations of KIT or platelet-derived
growth factor receptor alpha (PDGFRA) [2][3]. Imatinib mesy-
late, a small molecule inhibitor of KIT and PDGFRA, yields long-
lasting responses in the majority of patients [4], however, 80–90%
of the patients eventually develop secondary resistance and
progress with a dismal outcome. Despite major tumor shrinkage
and regressive changes seen in CT scans, resection specimen
contain viable tumor cells in most patients responding to imatinib
[5]. While this may be attributed to pre-existing clones harboring
secondary resistance mutations, these findings suggest that the
inhibition of the KIT oncogenic signal alone does not sufficiently
induce apoptosis.
The p53 transcription factor is an important cell cycle regulator
that plays a key role in the cellular defense against neoplastic
transformation [6]. Mutations of the TP53 gene are commonly
found in human tumors causing the expression of an inactive gene
product. In addition, p53 inactivation can be exerted by viral
oncogenic products, defects of its upstream regulator p14
ARF or
association of p53 protein with the murine double-minute 2
(MDM2) cellular oncoprotein [7][8]. MDM2, a major physiolog-
ical antagonist of p53, can bind the p53 transactivation domain,
thereby interfering with p53 transcriptional regulatory mecha-
nisms [7][9][10]. MDM2 is also an E3 ubiquitin ligase that
promotes p53 proteasomal degradation. MDM2 is overexpressed
in some human tumors by gene amplification, thus inactivating
p53 function. Reactivation of the p53 pathway through inhibition
of MDM2 may result in either induction of cell cycle arrest by
upregulation of p21 or induction of apoptosis even in the absence
PLoS ONE | www.plosone.org 1 May 2012 | Volume 7 | Issue 5 | e37776of MDM2 amplification [11]. Previous studies have demonstrated
that a prerequisite for a proapoptotic effect of MDM2 inhibitors
(MDM2i) in therapeutically relevant doses is the absence of
inactivating p53 mutations [11]. However, nutlin-3 has also been
shown to induce apoptosis in p53-null and p53-mutated cells via
p73 at higher doses [12].
While almost 50% of all human tumors harbor inactivating p53
mutations, these are thought to be rarely found in GIST, thus
rendering GIST to be potentially sensitive to reactivation of p53
[13].
Against this background we sought to evaluate p53 modulation
as a therapeutic approach in GIST using nutlin-3 and RITA, two
extensively characterized MDM2 inhibitors, both as a single agent
and in combination with drugs that inhibit the KIT oncogenic
pathway.
Results
Results of TP53 analysis in 62 GISTs
We screened 62 GISTs regardless of p53 or p21 expression
levels for TP53 mutations to determine how often p53-function is
depleted by inactivating mutations. Forty were primary and 22
were metastatic GISTs. We found a P72R-polymorphism in 37
out of the 40 primary and in 20 out of the 22 metastatic GISTs
(Tab. 1). Two out of 62 tumors showed a mutation, H193R in one
of the primary GISTs and H290P in one of the metastatic GIST
(Tab. 2). Most patients were untreated GISTs, the metastatic
GISTs harboring a TP53 mutation had failed multiple treatment
lines (imatinib, sunitinib, nilotinib and sorafenib).
TP53 sequencing analysis of GIST cell lines
We first sequenced TP53 in all GIST cell lines. No mutations
were found in TP53 (exon 1–12) in GIST430, GIST48 and
GIST48B. GIST-T1 and GIST882 were wild type for exons 2–12
and 1, 8–12 but we were unable to amplify the promotor region in
GIST882 and exons 2–7 in GIST-T1 suggesting homozygous
deletions in these regions (Fig. 1A/Tab. 3). RNA sequencing data
from several GIST cell lines supported the complete absence of
p53 transcript based on approximately 7610
7 exonic reads in
GIST882 compared to GIST48 and GIST430 (FigS1).
MDM2 inhibitors exhibit differential antiproliferative
effects in IM-resistant GIST cell lines
We evaluated the antiproliferative effects of nutlin-3 and RITA
in five GIST cell lines by treating cells for 6 days with increasing
concentrations of nutlin-3 and RITA (10 nM to 5 mM for RITA
and 10 nM to 10 mM for nutlin-3) using the sulforhodamin B
cytotoxicity assay. Nutlin-3 treatment resulted in antiproliferative
effects in all IM-resistant cell lines (GIST430, GIST48 and
GIST48B; IC50 4–10 mM), but not in IM-sensitive GIST882 and
GIST-T1 (IC50.10 mM; Fig. 1B). RITA treatment caused strong
antiproliferative effects in GIST-T1 and GIST48B (IC50 30 nM
and 200 nM, respectively), but showed only mild effects in other
cell lines (IC50.10 mM; Fig. 1C).
Effects of MDM2i and IM on the induction of apoptosis:
RITA induces apoptosis in GIST48B and GIST-T1
We then analyzed the effects of MDM2 inhibitors on the
induction of apoptosis using a luminescence based assay to
measure cleaved caspases 3 and 7 as well as by determining the
amount of apoptotic cells by flow cytometry using annexin V/7-
AAD staining. Nutlin-3 10 mM showed a 4-fold induction of
caspase 3/7 cleavage in GIST48B but not in any other GIST cell
line (Fig. 2, data not shown). A mild induction of apoptotic cells as
measured by flow cytometry was seen in all IM-resistant cell lines
but no effects were seen in GIST882 and GIST-T1. Treatment
with RITA 1 mM resulted in a 7-fold induction of cleaved caspase
3/7 in both GIST48B and GIST-T1 (Fig. 2A/B) correlating well
with cytometry studies (Fig. 2A/B). GIST48 was not affected by
RITA treatment (Fig. 2C/D). As expected, imatinib treatment
resulted in induction of annexin V/7AAD positive cells in the IM-
sensitive cell line GIST-T1, but not in the IM-resistant cell lines
GIST48 and GIST48B (Fig. 2A/B/C).
Effects of MDM2i and IM on the cell cycle: Nutlin-3
induces S-phase suppression in IM-resistant cell lines
We then performed cell cycle analyses to further evaluate the
effects of nutlin-3 and RITA. In the p53 wildtype cell lines,
treatment with nutlin-3 reduced cell proliferation. In GIST48
17.0% of cells were in S-Phase in the control sample, which was
reduced to 6.5% after 5 mM nutlin-3 treatment. The cells in G1-
Phase increased from 70.0% to 83.0% (FigS2). In GIST48B
nutlin-3 treatment reduced the S-Phase from 20.5% to 5.7% and
increased G1-Phase from 64.3% to 85.0% (FigS2). RITA induced
apoptotic cells in GIST48B and GIST-T1 (0.9% vs. 17.5% and
4.1% vs. 17.3%; FigS2). Furthermore, in GIST48 and GIST-T1
treatment with high doses of RITA (5 mM) increased the amount
of cells in S-Phase (17.0% vs. 51.6% and 12.6% vs. 35.2%) and
decreased the amount of cells in G1-Phase (70.0% vs. 35.8% and
71.9% vs. 48.7%) (FigS2).
Effects of MDM2i on p53 and p53 associated proteins
(MDM2, p21, cleaved caspase 3)
We further investigated the effects of nutlin-3 and RITA
treatment on p53 and p53-dependent signaling pathways by
western blot analysis. Figure 3A displays the effects of the indicated
treatment after 24 hours of incubation. Figure 3B is a time course
that covers the effects of nutlin-3 treatment at different time points
Table 1. TP53 sequencing results of 62 patients with primary
localized (n=40) or metastastic (n=22) GIST: P72R-
polymorphism status.
Amino Acid 72 GIST (n=62) %
Healthy Population*
(n=107) in %
Arg (R) homozygous 36 58 22
Pro/Arg heterozygous 21 34 65
Pro (P) wildtype 5 8 12
doi:10.1371/journal.pone.0037776.t001
Table 2. TP53 sequencing results of 62 patients with primary
localized (n=40) or metastastic (n=22) GIST.
Stage/tissue
no.pts
(n=62) Mutation %
Polymorphism
(P72R) %
very low 5 0 0% 5 100%
low 10 0 0% 10 100%
moderate 9 1 (H193R) 11% 8 89%
high 16 0 0% 14 87%
metastatic 22 1 (H290P) 5% 20 91%
doi:10.1371/journal.pone.0037776.t002
MDM2/p53 Modulation in GIST
PLoS ONE | www.plosone.org 2 May 2012 | Volume 7 | Issue 5 | e37776Figure 1. Results of TP53 sequencing and MDM2i treatment in GIST cell lines. A: TP53 sequencing in all GIST cell lines. Dashed lines indicate
that the product of the given exon/intron could not be amplified. B+C: Sulforhodamin-based cytotoxicity assays for nutlin-3 (A) and RITA (B) in IM-
sensitive (GIST882, GIST-T1) and IM-resistant (GIST48, GIST48B, GIST430) cell lines. All cells were treated with the indicated concentrations and
assessed after 6 days of treatment, with the data normalized to DMSO-only controls. X=0 is DMSO-only treated. Lines, KIT-positive cell lines; dotted
lines, KIT-negative cell lines, points, mean of quadruplicate cultures; bars, SD.
doi:10.1371/journal.pone.0037776.g001
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10 mM) strongly induced p53 expression after 60 minutes, as well
as MDM2 and p21 expression after 90 minutes in IM-resistant cell
lines GIST48, GIST48B and GIST430. GIST882 and GIST-T1
(Fig. 3A/B) did not express p53 at baseline or after MDM2
inhibition. In GIST48B, 10 mM treatment led to substantial
caspase 3 cleavage (Fig. 3A).
In GIST48B treatment with RITA strongly induced p53 after
90 minutes and a cleavage of caspase 3 after 24 h, without
affecting levels MDM2 or p21 (Fig. 3A/B). In GIST-T1 RITA
treatment induced a marked cleavage of caspase 3, but no
induction of MDM2 (Fig. 3A/B).
Nutlin-3 inhibits the binding of MDM2 to p53 and hnRNP
K
To test whether MDM2i act by disrupting the binding between
MDM2 and p53, we performed an immunoprecipitation of
MDM2. Treatment of GIST48B cells for 24 h with nutlin-3 lead
to a relative reduction of MDM2 binding to p53 (Fig. 3C). RITA
treatment did not seem to affect the binding of MDM2 to p53
(Fig. 3C).
To further elucidate the mechanisms of action of MDM2i, we
also examined the binding of heterogeneous nuclear ribonucleo-
protein K (hnRNP K), a p53 cofactor, to MDM2 before and after
treatment. Neither nutlin-3 nor RITA affected the overall level of
hnRNP K expression in our western blot analysis (Fig. 3A/B/C).
However, immunoprecipitation showed that the binding between
MDM2 and hnRNP K was significantly reduced after nutlin-3
treatment but not after RITA treatment (Fig. 3C). This could
indicate that after RITA treatment MDM2 can still bind and
potentially degradate hnRNP K.
Phosphorylation of p53 at Serine 46
Several kinases are able to activate p53 by phosphorylation at
different sites. Phosphorylation of Serine 46 is known to initiate
apoptosis, rather than induce cell cycle arrest. One of the kinases
known to phosphorylate at that site is the homeodomain-
interacting protein kinase 2 (HIPK2) [14]. Rinaldo et al. have
proposed that nutlin-3 treatment degrades and RITA treatment
activates HIPK2, leading to a stronger phosphorylation of p53 and
subsequently to a stronger induction of apoptosis [15]. We
therefore performed p53 and phospho (Serine 46)-p53 immuno-
precipitations to analyse whether nutlin-3 or RITA treatment has
any effects on p53 phosphorylation at Serine 46.
However, the phospho p53 and total p53 staining revealed that
both nutlin-3 and RITA induced phosphorylation at Serine 46
(Fig. 3C).
To address the total levels of HIPK2 in our cell lines before and
after treatment with MDM2i, we performed another western blot
analysis. In GIST48B treatment with RITA and nutlin-3 did not
alter the level of HIPK2 expression (Fig. 3D). However, in other
cell lines the baseline expression of HIPK2 was lower and RITA
treatment led to a downregulation of HIPK2, as shown for
GIST430 (Fig. 3D).
Nutlin-3 enhances the induction of apoptosis of different
KIT-inhibitory drugs
We also studied the effects of combinational treatment of nutlin-
3 and different direct and indirect KIT-inhibitory drugs using
therapeutically relevant doses of nutlin-3 [11].
Adding nutlin-3 to IM in IM-resistant GIST430 and GIST48
had little or no effect on caspase 3 and 7 activation (Fig. 4A). The
HSP90-inhibitor 17-AAG potently inhibits oncogenic KIT
regardless of secondary IM-resistance mutations. A combination
of 17-AAG and nutlin-3 resulted in an additive proapoptotic effect
in the IM-resistant cell lines GIST430, GIST48 and GIST48B, as
measured by western blot-, luminescence- and annexin V/7-AAD-
assays, shown for GIST430 and GIST48 (Fig. 4A/B/FigS3).
Nutlin-3 has no effect on KIT-dependent signaling
pathways
Constitutively activated KIT represents the key oncogenic
driver in GIST that promotes proliferation and has antiapoptotic
effects. Thus, any disruption within the KIT-signaling pathway
may directly influence the growth and survival of cells. To exclude
possibly antagonistic off-target effects within this signaling pathway
we treated cells with nutlin-3 alone and in combination with
different KIT-inhibitory drugs. Western blot analyses were
performed to investigate the effects of nutlin-3 treatment on
KIT-signaling in the presence or absence of KIT-inhibitory drugs.
IM treatment alone only partially inhibited phosphorylation of
KIT and AKT, yet not of MAPK in both GIST430 and GIST48
(Fig. 4B), as typically observed in imatinib-resistant cells. Sunitinib
(SU) treatment alone inhibited phosphorylation of KIT and AKT
in GIST430, but not in GIST48 (Fig. 4B), which is expected as SU
potently inhibits secondary KIT exon 13 mutations (GIST430) but
not kinase loop mutations in exon 17 (GIST48). The HSP90
inhibitor 17-AAG, which has been shown to inhibit KIT
regardless of secondary mutations, inhibits KIT and KIT-
dependent signaling in both cell lines. IM, SU and 17-AAG did
not affect expression levels of p53, MDM2 or p21 at this time
point (Fig. 4B).
Nutlin-3 treatment did not affect expression levels of KIT and
KIT-dependent signaling pathways in any combination (Fig. 4B).
In addition, no antagonistic effects were seen in any combination,
including imatinib, sunitinib, sorafenib, 17-AAG, SAHA, nilotinib
and dasatinib (data not shown), as measured by SRB assays in any
tested GIST cell line.
Table 3. TP53 sequencing results of 5 GIST cell lines.
Stage/tissue no. (n=5) Mutation % Polymorphism (P72R) %
Cell lines 5 2 40% 1 20%
GIST882 suspected deletion Exon 1 1
GIST T1 suspected deletion Exon 2–7
GIST430 -
GIST48B -
GIST48 -
doi:10.1371/journal.pone.0037776.t003
MDM2/p53 Modulation in GIST
PLoS ONE | www.plosone.org 4 May 2012 | Volume 7 | Issue 5 | e37776Figure 2. Induction of apoptosis represented by amount of activated caspases 3 and 7 (graphs on the left side) and annexin V/7-
AAD based FACS assay (graphs on the right side) in GIST48B (A), GIST-T1 (B), GIST48 (C) and GIST430 (D). Indicated concentrations of
the inhibitors were assayed after 24 h and 48 h of incubation. DMSO was vehicle control. Bars, mean of quadruplicate cultures with SD represent
multitudes of DMSO-only values. N=nutlin-3.
doi:10.1371/journal.pone.0037776.g002
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PLoS ONE | www.plosone.org 5 May 2012 | Volume 7 | Issue 5 | e37776Figure 3. Western Blot analyses of nutlin-3 and RITA effects on p53 and p53-dependent signalling pathways. A: Western Blot analyses
after 24 h of incubation with doses of nutlin-3 (5 mM and 10 mM) and RITA (1 mM and 5 mM) in GIST48, GIST48B, GIST-T1, GIST882 and GIST430. B:
Time course study in GIST48B. Cells treated for indicated intervals with nutlin-3 5 mM and RITA 1 mM. C: Immunoprecipitation of MDM2, p53 and
phospho-p53 from GIST48B cell lysates treated with DMSO, nutlin-3 5 mM and RITA 1 mM for 24 h hours. Staining of whole cell lysates (Inputs) for the
indicated proteins. D: Western Blot analyses after 24 h of incubation with doses of nutlin-3 (5 mM and 10 mM) and RITA (15 mM) in GIST48B and
GIST430.
doi:10.1371/journal.pone.0037776.g003
MDM2/p53 Modulation in GIST
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To gain further understanding of the differential sensitivity of
GIST cells to nutlin-3, we performed a quantitative real time PCR
evaluation of TP53 and MDM2 mRNA in GIST882, GIST-T1
and GIST48B. In GIST48B nutlin-3 and RITA treatment
resulted in a small (10%) and treatment with doxorubicin resulted
in a stronger increase (50%) in TP53 mRNA levels (Fig. 5A).
MDM2 mRNA levels were strongly increased by nutlin-3 (16- to
37-fold) and doxorubicin treatment (6-fold), but only mildly after
RITA treatment (10%) (Fig. 5A). In GIST882 and GIST-T1
however, TP53 mRNA levels were not detectable (Fig. 5A).
MDM2 mRNA levels were slightly increased by nutlin-3- and
doxorubicin treatment and minimally reduced after RITA
treatment (Fig. 5A). These findings correlate with our findings in
the western blot analysis: In contrast to GIST48B p53 and MDM2
proteins were not detectable in GIST882 and GIST-T1 despite
treatment with high doses of nutlin-3 or doxorubicin (Fig. 5B).
Analysis of the p53 homologes p63 and p73 and p53
dependent proteins
It has been shown that nutlin-3 treatment can induce apoptosis
in higher doses in a p53 independent manner, via p73 [12].
Therefore, we analyzed the expression of different members of the
p53 family, p63 and p73, in response to MDM2i treatment in
different cell lines. P73 expression levels were high in all the GIST
cell lines (FigS4A) compared to the positive control cell line MCF7
and HeLa. P73 expression was slightly increased (2-fold) after
nutlin-3 treatment in GIST882 and GIST430 but not in the other
cell lines (FigS4A). P63 was undetectable in GIST430, GIST48
and GIST-T1 and weakly expressed in GIST882 and GIST48B.
The proapoptotic protein BAX, known to be transcriptionally
regulated by p53, was expressed in all the GIST cell lines, with
higher levels in p53 positive cell lines (2–3 -fold) (FigS4A). In these
cell lines, nutlin-3 also mildly induced BAX while RITA treatment
had no effect on BAX levels (FigS4A).
Discussion
Complete pathological remissions of metastatic GISTs following
treatment with IM represent a rare exception. Mechanisms of
(late) resistance to IM have been widely described and comprise
secondary mutations with a large degree of genomic heterogeneity
[16], loss of c-KIT expression [5], c-kit amplification, and rarely
BRAF mutations [17]. It is of yet unknown, whether these changes
occur upon treatment with imatinib or if clones with pre-existing
secondary mutations are selected for during treatment.
Treatment of imatinib-sensitive cell lines with IM in vitro causes
only modest induction of apoptosis [18] suggesting, that combi-
national treatments with proapoptotic drugs may be needed to
push cells into apoptotic death. For proof of concept studies we
used two p53 modulating drugs, nutlin-3 and RITA, which have
Figure 4. Analysis of nutlin-3 in combinational treatment. A: Induction of apoptosis represented by amount of activated caspases 3 and 7 in
GIST430 and GIST48. Indicated concentrations of nutlin-3 were assayed alone and in combination with different KIT-inhibitors after 24 h and 48 h of
incubation. DMSO was vehicle control. Bars, mean of quadruplicate cultures with SD represent multitudes of DMSO-only values. B: Western Blot
analyses after 24 h of incubation with doses of nutlin-3 (5 mM) alone and in combination with different KIT-inhibitors in GIST430 and GIST48.
N=nutin-3, IM=imatinib mesylate, SU=sunitinib.
doi:10.1371/journal.pone.0037776.g004
MDM2/p53 Modulation in GIST
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imidazoline analogue that binds MDM2 in the p53 binding pocket
and thus inhibits interaction with p53. Subsequently MDM2 can
no longer repress p53 by blocking its transactivation site and by
tagging it for proteasomal degradation [11]. RITA is a furanic
compound, which is thought to bind, among other molecules, to
the p53 NH2-terminal domain, inhibiting it from binding to
MDM2. This is supposed to preserve MDM2 E3-ligase activity
and MDM2 mediated degradation of other MDM2 clients. It has
been proposed that some of these other clients might be anti-
apoptotic p53 cofactors and by preserving MDM2 E3-ligase
activity the apoptotic response to p53 activation might be stronger
after RITA treatment, compared to the nutlin-3 treatment
[15][19].
Our studies showed a surprisingly differential sensitivity of the
panel of GIST cell lines towards nutlin-3 and RITA. Nutlin-3
treatment alone showed only moderate growth inhibition and
weak induction of apoptosis in IM-resistant cell lines, but no effects
in the IM-sensible GIST882 and GIST-T1 (Fig. 1). This
corresponded well with the observation that, in contrast to IM-
resistant GIST cell lines, GIST882 and GIST-T1 neither had
baseline expression of p53 nor showed induction of p53 upon
treatment with high doses of nutlin-3 or doxorubicin (Fig. 3,
Fig. 5B). Since the lack of nutlin-3 response is predictive of
dysfunctional p53 we performed quantitative RT-PCR for p53
and MDM2 following nutlin-3, RITA and doxorubicin treatment,
which did not result in a detectable induction of p53 in GIST882
and GIST-T1. We were unable to amplify the promotor region in
GIST882 and exon 2 through 7 in GIST-T1 (Fig. 5C) suggesting a
homozygous deletion. A large deletion was excluded by 250K SNP
arrays in both cell lines (J. Fletcher, data not shown). This finding
is noteworthy given the wide use of both cell lines for drug
validation studies in GIST and the potential bias this may cause
for studying apoptosis in these cell lines. Very little data is available
on the incidence of p53 mutations in GIST. A study by Romeo et
al. in patients with untreated metastatic GISTs (n=353) found
16% of mutations (n=13) in a subgroup of patients with high p53
and low p21 expression (n=79) [13]. We performed a mutational
analysis in 62 additional tumors of both localized and metastatic
GISTs regardless of p53 expression data (Tab. 1 and Tab. 2).
While the P72R polymorphism was commonly found in the
majority of our patients, classical TP53 mutations were rare (3%).
Our data therefore support the previous data, that TP53 mutations
in GIST may be an exception at least in untreated patients, which
would be a prerequisite for the clinical use of p53-modulating
drugs in GIST. While other genetic events have been described to
dysregulate the p53 pathway in GIST, such as deletions of p16 or
amplification of MDM2, these would not preclude the use of
MDM2 inhibitors but could rather sensitize cells to a treatment
[20,21]. To our surprise, two out of the five commonly used GIST
cell lines harbor deletions in TP53. Cultivation of GIST cells is
particularly difficult and most short-term cultures exhibit senes-
cence after few passages. However, TP53 mutations may represent
a selection advantage in vitro, which might explain the presence in
cell lines that were derived from imatinib-naı ¨ve metastatic GISTs.
Although the P72R polymorphism is very commonly found in the
healthy population it has nonetheless been associated with familiar
breast cancer in Jewish women. In our study, 60% of GIST
patients had a homozygous polymorphism compared to 22% in
the historical control [22].
Figure 5. Effects of different inhibitors on p53 and MDM2 mRNA and protein levels. A: Quantitative Real Time RT-PCR evaluation of p53
and MDM2 mRNA in GIST882, GIST T1 and GIST48B after treatment of different concentrations of nutlin-3 (10 mM and 20 mM) and RITA (5 mM). Values
were normalized to the DMSO value for each point in time. B: Western Blot studies of GIST882, GIST-T1 and GIST48B treated with nutlin-3 20 mM and
Doxorubicin 0.5 mM for 24 h. N=nutlin-3, Doxo=Doxorubicin.
doi:10.1371/journal.pone.0037776.g005
MDM2/p53 Modulation in GIST
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antiproliferative effect in p53 wild-type GIST but not in a strong
induction of apoptosis. As hypothesized by Enge et al, this may be
due to the induction of the anti-apoptotic protein p21, which was
seen after nutlin-3 but not after RITA treatment (Fig. 3) [19]. Our
findings suggest that in the GIST context, when given alone,
nutlin-3 induces cell cycle arrest rather than apoptosis (FigS2).
This may be a tumor specific effect, as Vasilev and colleagues
recently showed that p21 may not decrease the apoptotic response
to nutlin-3 in other cell systems [23]. Of note, GIST cell lines
showed different sensitivity profiles towards RITA and nutlin-3.
The group of Selivanova has recently described several mecha-
nisms that may explain differential effects seen with RITA and
nutlin-3 involving the p53 co-factor hnRNP K as well as the p53-
activator HIPK2 [15,19]. HnRNP K has been described by Enge
et al. as an important cofactor of p53 induced cell cycle arrest [19].
HnRNP K is also a client of MDM2 and it has been proposed that
RITA, in contrast to MDM2-bound nutlin-3, causes degradation
of hnRNP K by the fully functional MDM2. Enge et al. showed
that RITA treatment decreased both the overall levels of hnRNP
K and the binding of hnRNP K to MDM2 [19]. Selivanovas
group also showed that nutlin-3 treatment downregulated HIPK2
while RITA treatment resulted in kinase activation. The
subsequent phosphorylation of p53 at Serine 46 was reported to
contribute to the rather proapoptotic effects of RITA [15]. In
GIST, RITA did not have an effect on hnRNP K expression.
Regarding HIPK2 activation, RITA treatment did not induce a
stronger phosphorylation of p53 at S46, compared to the nutlin-3
treatment. All this implicates a different mechanism of action for
RITA in this cellular context.
While p53 mutational status was predictive for response to
nutlin-3, RITA showed a differential activity in the same GIST
cell line panel. GIST48B and GIST-T1 were particularly sensitive
to RITA, despite the absence of p53 in the latter. Notably, these
effects were not a result of an activation of p63 or p73, which has
previously been described as an alternative mechanism for
induction of apoptosis by MDM2-inhibitory drugs [12]. In
addition, in contrast to nutlin-3, RITA also did not inhibit the
MDM2/p53 interaction as shown by immunoprecipitation in
GIST48B (Fig. 3C). Supporting evidence for p53-independent
effects of RITA were also found in the more widely used
osteosarcoma cell line SAOS-2 [24] (p53-null) (FigS4C). A
potential explanation for p53-independent effects of RITA were
reported by Yang et al, who described a novel mechanism of
action for RITA through induction of DNA-damage response
[25]. Proapoptotic function of mutated p53 may also be rescued by
RITA as shown by Zhao et al. [26]. Together with our findings,
these data suggest a more complex and less predictable mechanism
of action for RITA.
Future studies should therefore investigate the early events
preceding the onset of apoptosis in GIST-T1 and GIST48B
following RITA treatment, which may help to identify additional
targets for proapoptotic treatments.
Combinational treatments with several KIT-inhibitory drugs
and the HSP90 inhibitor 17-AAG showed additive proapoptotic
effects with nutlin-3 if effective KIT-inhibition was achieved. KIT
and KIT-depending signaling pathways were not affected by
nutlin-3 alone, nor did nutlin-3 influence the effect of KIT-
inhibitory drugs on KIT-dependent signaling. In GIST430, a cell
line harboring an IM-resistance mutation in exon 13, nutlin-3
treatment improved the apoptotic response to sunitinib, which is
known to effectively inhibit KIT exon 13 mutations [27]. In
contrast, GIST48, harboring an exon 17 resistance mutation,
nutlin-3 did not show additive effects with imatinib or sunitinib.
However, a pronounced additive effect was seen with 17-AAG,
which effectively inhibits KIT-activation regardless of underlying
KIT mutations [28]. These results imply that a combinational
treatment with p53-activating drugs would require an effective
shut down of the oncogenic KIT-signal. This correlates with the
results of Kurosu et al., who were able to show that nutlin-3
treatment enhanced the induction of apoptosis of IM treatment in
BCR/ABL positive leukemia cell lines [29]. Importantly, no
antagonistic effects have been observed with any treatment
combination.
In summary, our studies provide the first promising evidence
that modulators of the MDM2/p53 pathway may enhance the
apoptotic response to KIT-inhibitory treatments in GIST. In the
GIST context, nutlin-3-type inhibitors seem more predictable than
furanic compounds since their activity relies on functional p53.
Materials and Methods
Cell lines
GIST-T1 was established from a human, untreated, metastatic
GIST containing a 57 bp deletion in KIT exon 11 which is highly
sensitive to IM at low nanomolar doses [30]. GIST-T1 harbours a
homozygous deletion. GIST882, as previously described, was
established from an untreated human GIST with a homozygous
missense mutation in KIT exon 13, encoding a K642E mutant
KIT oncoprotein which is sensitive to IM [31]. We were unable to
amplify the TP53 promotor region, also suggesting a homozygous
deletion in this region. Both GIST-T1 and GIST882 were p53
negative as measured by qRT-PCR and western blot analysis.
GIST48 was established from a GIST that had progressed, after
initial clinical response, during IM therapy. GIST48 has a
primary, homozygous KIT exon 11 missense mutation (V560D)
and a heterozygous secondary KIT exon 17 (kinase activation loop)
mutation (D820A) [28]. GIST48 is IM-resistant, due to a
secondary KIT exon 17 mutation. GIST48B is a subline of
GIST48 which, despite retaining the activating KIT mutation in all
cells, expresses KIT transcript (data not shown) and protein at
essentially undetectable levels [32]. GIST430 was also established
from a GIST that progressed during IM therapy. It has a primary
heterozygous KIT exon 11 in-frame deletion and a heterozygous
secondary KIT exon 13 missense mutation that confers IM
resistance [28]. GIST48, GIST48B and GIST430 are TP53 wild
type and express p53 RNA and protein as measured by qRT-PCR
and western blot analysis. The liposarcoma cell line LPS141 is
highly sensitive to MDM2 inhibition due to high-level amplifica-
tion of MDM2 and served as positive control [32]. All cell lines
except for GIST-T1 have been established at the Brigham and
Women’s Hospital in Boston, USA, by the Group of Professor
Jonathan A. Fletcher. GIST-T1 has been established by Takahiro
Taguchi at the Kochi University in Japan.
Reagents and Antibodies
Nutlin-3 (racemate of nutlin-3a and its inactive enantiomere
nutlin-3b) was purchased from Sigma Aldrich. RITA and SAHA
were purchased from Cayman Chemical (Ann Arbor, Michigan).
Imatinib (IM) and sunitinib (SU) were purchased from Sequoia
Research Products (Pangbourne, UK). Dasatinib, Nilotinib and
Sorafenib were purchased from LC Laboratories (Woburn, MA).
17-N-Allylamino-17-demethoxygeldanamycin (17-AAG) was pur-
chased from Calbiochem (Merck, Darmstadt, Germany).
A rabbit polyclonal antibody to KIT was from DAKO
(Carpinteria, CA). Polyclonal rabbit antibodies to phospho-KIT
Y703 and mouse MDM2 antibody were from Zymed Laboratories
(South San Francisco, CA). Polyclonal rabbit antibodies to
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(MAPK), phospho-p44/42 MAPK T202/Y204, phospho-AKT
S473, total AKT, phospho-KIT Y719, cleaved caspase-3 were
from Cell Signaling (Beverly, MA). p21 and Beta Actin antibodies
were purchased from Sigma (St. Louis, MO). Mouse p53 antibody
was purchased from BD Pharmingen (Franklin Lakes, NJ), mouse
hnRNP K antibody from Imuno Quest (North Yorkshire, UK)
and MDM4 rabbit antibody from Bethyl Laboratories (Mon-
tgomery, TX). HIPK2 antibody was kindly provided by Prof
Lienhard Schmitz (University of Giessen).
In vitro assays
Viability studies were carried out using a Sulforhodamin (SRB)
assay [33]. For these studies, the cell lines were plated at 15,000 to
30,000 cells per well in a 96-well flat-bottom plate (Falcon,
Lincoln, NJ), cultured in serum-containing media for 1 day, and
then incubated for 72 or 144 hours with MDM2-, or KIT-
inhibitors and DMSO-only solvent control. The SRB assay
absorption was measured with a Genion Luminometer (Tecan,
Crailsheim, Germany) and the data were normalized to the
DMSO-only control group. All experimental points were mea-
sured in triplicate or quadruplicate wells for each plate and were
replicated in at least two plates.
Apoptosis studies were done by measuring caspase-3 and
caspase-7 activation with the Caspase-Glo 3/7 Assay Kit
(Promega). This assay uses a proluminescent substrate containing
the DEVD sequence recognized and activated by caspase-3 and
caspase-7 [34,35] and the luminescence signal is proportional to
net caspase-3 and caspase-7 activation [36]. The experimental
conditions were all as described above for the SRB studies except
treatment duration of 24 and 48 hours.
Western blotting and immunoprecipitation
Protein lysates were prepared from cell line monolayers
according to standard protocols [37]. Protein concentrations were
determined with the Bio-Rad Protein Assay (Bio-Rad Laborato-
ries, Hercules, CA). Electrophoresis and immunoblotting were
carried out as previously described [38]. Changes in protein
expression and phosphorylation as visualized by chemilumines-
cence were captured and quantified using a FUJI LAS3000 system
with Science Lab 2001 ImageGauge 4.0 software (Fujifilm Medial
Systems, Stamford CT, USA).
Immunoprecipitations were performed with Sepharose protein
G beads (Zymed Laboratories) from 400–600 mg of total protein as
described previously [34].
Cell cycle analysis
Cells were plated in six-well plates, grown until 80% confluence,
and then treated for 48 hours with DMSO, nutlin-3 (5 mM and
10 mM), RITA (1 mM and 5 mM) or IM (500 nM). Cells were then
trypsinized and stained with DNA prep containing propidium
iodide (PI) (Beckman Dickonson, Heidelberg, Germany) followed
immediately by flow cytometric analysis (BeckmanCoulter FC500
Flow Cytometer). Modfit LT software 3.1 (Verity Software House,
Topsham, ME) was used for data analysis.
Cell viability assessment by Annexin V Staining
After drug treatments as described for the cell cycle analysis
above, cells were resuspended in 500 ml of the staining buffer and
annexin V FITC (525 nm) and 7-AAD (675 nm) (BD) were added.
After incubation at room temperature for 15 min, annexin V-
positive cells were estimated by flow cytometry. 10000 events of
each sample were acquired on a BeckmanCoulter FC500 Flow
Cytometer. Doublet discrimination was done with FL2 vs. FL2
peak histogram.
Quantitative Real Time Reverse Transcriptase-PCR
Cells were plated in 12-well plates, grown until 80% confluence,
and then treated with drug-containing media. Cells were then
collected with RNAprotect Cell reagent (Qiagen, Hilden,
Germany) and processed with RNeasy Mini Kit (Qiagen)
according to the manufacturer’s protocol, for RNA isolation.
cDNA was transcribed by Reverse Transcriptase-PCR using
random primers and KIT-cDNA was amplified and measured
using TaqMan gene expression assays (Applied Biosystems, Softer
City, CA) and Real Time PCR system LightCycler 480 (Roche,
Grenzach-Wyhlen, Germany). Beta-Actin cDNA, (also measured
using TaqMan gene expression assay (AB)) served as reference
gene for relative quantification.
P53 sequencing of GIST cell lines and a panel of primary
GIST
Genomic DNA was extracted from 10 mm sections of the
paraffin-embedded tumor blocks used for immunohistochemistry,
using a macrodissection technique to reduce contamination with
nonneoplastic tissue, from fresh frozen tumor samples and from
cell lines. Genomic DNA was isolated using the QIAmp DNA
Mini Kit. PCR was done on TP53 for exons 4 to 9 (primers are
listed in Tab. 4) in GIST tumors and for exons 1 to 12 in all GIST
cell lines. 10 mL PCR reactions consisted of 20 ng input genomic
DNA, 106HotMAster Taq buffer with 25 mM MgCl2, 2.5 units
HotMaster Taq DNA polymerase (5 Prime). PCR was carried out
at an initial denaturation step of 2 min at 95uC, followed by 40
cycles of 20 s at 95uC, 10 s at 60uC, and 35 s at 65uC, and a final
elongation step of 10 min at 72uC. Nucleotide sequence analysis
was performed with the BigDye Terminator v1.1 Cycle Sequenc-
ing Kit (Applied Biosystems, Foster City, CA, USA). The purified
PCR products were sequenced in both directions. Cycle sequenc-
ing products were analyzed using the ABI PRISM 310 Genetic
Analyser (Applied Biosystems, Darmstadt, Germany).
Whole transcriptome sequencing
rRNA was depleted from 5 mg of total RNA using biotinylated
oligonucleotides (Ribominus, Invitrogen), and libraries were
constructed from the rRNA-depleted RNA according to the
SOLiD Total RNA-seq Kit Protocol (Applied Biosystems). Briefly,
library construction involved fragmentation of the RNA by RNAse
III to an average size of 150 bases, ligation of the fragmented RNA
to adaptors in a directed orientation, then cDNA synthesis and
PCR amplification of the resulting library. Approximately 50 bases
were sequenced from one end of each fragment using either the
SOLiD 3+ or SOLiD 4 instrument and reagents (Applied
Biosystems). The resulting sequence data was mapped to the
human reference genome, hg18, using Bioscope v1.2 (Applied
Biosystems). Sequences that mapped to unique locations were
quantified per transcriptional unit, as defined in RefSeq (release
35), as ‘‘reads per kilobase of transcript per megabase of total
sequence (RPKM).’’
A weighted score, described by the following expression:
Sk~
Yk{Xk ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
max XkYk’1000 ðÞ
p |log10 max XkYk’1000 ðÞ ½ 
was used to rank the difference in normalized reads for each
transcript between samples.
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Figure S1 Whole transcriptome sequencing data for p53
demonstrates no detectable levels of p53 in GIST882 compared
to regular transcriptional levels in GIST430 and GIST48.
N=nutlin-3.
(EPS)
Figure S2 Cell cycle analysis FACS assay in GIST48 (A),
GIST48B (B) and GIST T1 (C). Inhibitor concentrations were
used as indicated and assayed after 48 h of incubation. DMSO
was used as vehicle control. N=nutin-3, IM=imatinib mesylate,
SU=sunitinib.
(EPS)
Figure S3 Induction of apoptosis as measured by an Annexin/
7AAD based FACS Assay in GIST430 (A) and GIST48 (B).
N=nutin-3, IM=imatinib mesylate.
(EPS)
Figure S4 Analysis of apoptosis related proteins and effects of
MDM2i in p53-null SAOS-2 cells. A: Western Blot analyses after
24 h of incubation with doses of nutlin-3 (5 mM) and RITA (1 mM)
in GIST48, GIST48B, GIST-T1, GIST882 and GIST430. HELA
and MCF-7 cell serve as positive controls for p63 and p73. B:
Sulforhodamin-based cytotoxicity assays for nutlin-3 and RITA in
p53-null SAOS-2 cell line. C: Induction of apoptosis represented
by amount of activated caspases 3 and 7 in SAOS-2. Indicated
concentrations of the inhibitors were assayed after 24 h and 48 h
of incubation. DMSO was vehicle control. Bars, mean of
quadruplicate cultures with SD represent multitudes of DMSO-
only values.
(EPS)
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